JP6219372B2 - 放射性医薬錯体 - Google Patents

放射性医薬錯体 Download PDF

Info

Publication number
JP6219372B2
JP6219372B2 JP2015510840A JP2015510840A JP6219372B2 JP 6219372 B2 JP6219372 B2 JP 6219372B2 JP 2015510840 A JP2015510840 A JP 2015510840A JP 2015510840 A JP2015510840 A JP 2015510840A JP 6219372 B2 JP6219372 B2 JP 6219372B2
Authority
JP
Japan
Prior art keywords
moiety
thorium
tissue
moieties
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015510840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517483A (ja
Inventor
ハンネ セレセ ボンゲ−ハンセン，
ハンネ セレセ ボンゲ−ハンセン，
オラブ ベンジャミン ライアン，
オラブ ベンジャミン ライアン，
Original Assignee
バイエル・アーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル・アーエス filed Critical バイエル・アーエス
Publication of JP2015517483A publication Critical patent/JP2015517483A/ja
Application granted granted Critical
Publication of JP6219372B2 publication Critical patent/JP6219372B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
JP2015510840A 2012-05-11 2013-05-13 放射性医薬錯体 Expired - Fee Related JP6219372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes
GB1208309.3 2012-05-11
PCT/EP2013/059841 WO2013167756A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Publications (2)

Publication Number Publication Date
JP2015517483A JP2015517483A (ja) 2015-06-22
JP6219372B2 true JP6219372B2 (ja) 2017-10-25

Family

ID=46458687

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015510840A Expired - Fee Related JP6219372B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体
JP2015510839A Pending JP2015523326A (ja) 2012-05-11 2013-05-13 放射性医薬錯体
JP2015510838A Expired - Fee Related JP6211066B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015510839A Pending JP2015523326A (ja) 2012-05-11 2013-05-13 放射性医薬錯体
JP2015510838A Expired - Fee Related JP6211066B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体

Country Status (9)

Country Link
US (3) US20150147272A1 (enExample)
EP (3) EP2846843A1 (enExample)
JP (3) JP6219372B2 (enExample)
KR (3) KR20150092701A (enExample)
CN (3) CN104602716A (enExample)
CA (3) CA2873143A1 (enExample)
GB (1) GB201208309D0 (enExample)
HK (3) HK1207307A1 (enExample)
WO (3) WO2013167754A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
WO2011025790A1 (en) 2009-08-24 2011-03-03 Lumiphore, Inc. Macrocyclic hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10821195B2 (en) * 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
EP3432936A1 (en) 2016-03-24 2019-01-30 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
US20210017277A1 (en) * 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
KR20210116437A (ko) * 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
USD885822S1 (en) 2018-12-14 2020-06-02 Whirlpool Corporation Food grinder
WO2020169537A1 (en) 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
WO2020169538A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
WO2021142258A1 (en) * 2020-01-10 2021-07-15 Fusion Pharmaceuticals Inc. Macrocyclic chelates and uses thereof
CN115916731A (zh) * 2020-01-23 2023-04-04 瑞德兰有限责任公司 用于制备定制的放射性同位素溶液的系统和方法
US20240000838A1 (en) * 2020-11-30 2024-01-04 Simcere Innovation, Inc. Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
JPWO2025058000A1 (enExample) 2023-09-13 2025-03-20

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5624901A (en) * 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EP1763372B1 (en) * 2004-06-25 2016-11-30 The European Union, represented by the European Commission Radionuclides for medical use
US7794691B2 (en) * 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008063721A2 (en) 2006-08-15 2008-05-29 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
US8158804B2 (en) 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
JP5985392B2 (ja) * 2009-07-22 2016-09-06 アクティニウム ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体を生成するための方法
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
CA2873144C (en) 2021-03-16
US20150147272A1 (en) 2015-05-28
EP2846843A1 (en) 2015-03-18
CN104540530A (zh) 2015-04-22
JP2015517482A (ja) 2015-06-22
EP2846844B1 (en) 2020-04-01
US20150110817A1 (en) 2015-04-23
KR20150092700A (ko) 2015-08-13
WO2013167756A1 (en) 2013-11-14
KR20150092702A (ko) 2015-08-13
US20150104385A1 (en) 2015-04-16
HK1206981A1 (en) 2016-01-22
JP6211066B2 (ja) 2017-10-11
CN104602716A (zh) 2015-05-06
WO2013167754A1 (en) 2013-11-14
JP2015523326A (ja) 2015-08-13
WO2013167755A1 (en) 2013-11-14
HK1207307A1 (zh) 2016-01-29
EP2846844A1 (en) 2015-03-18
HK1206982A1 (en) 2016-01-22
CA2873142A1 (en) 2013-11-14
GB201208309D0 (en) 2012-06-27
EP2846842A1 (en) 2015-03-18
CA2873143A1 (en) 2013-11-14
US9827336B2 (en) 2017-11-28
JP2015517483A (ja) 2015-06-22
CN104619355A (zh) 2015-05-13
CA2873144A1 (en) 2013-11-14
KR20150092701A (ko) 2015-08-13

Similar Documents

Publication Publication Date Title
JP6211066B2 (ja) 放射性医薬錯体
JP6125599B2 (ja) アルファ放出複合体
AU2021202665B2 (en) Radio-pharmaceutical complexes
CN110357967B (zh) 新型成像组合物及其用途
JP2023076712A (ja) 放射標識生体分子およびその使用
HK1239540B (en) Radio-pharmaceutical complexes
HK1239540A1 (en) Radio-pharmaceutical complexes
EA043221B1 (ru) Радиофармацевтические комплексы

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20151008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170927

R150 Certificate of patent or registration of utility model

Ref document number: 6219372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees